Refractory gastroesophageal reflux disease: advances and treatment

References

• Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-20; quiz 1943
   PubMed Web of Science ®Google Scholar
• Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56
   PubMed Web of Science ®Google Scholar
• de Souza Cury M, Ferrari AP, Ciconelli R, et al. Evaluation of health-related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazole. Dis Esophagus 2006;19:289-93
   PubMed Web of Science ®Google Scholar
• Fass R, Gasiorowska A. Refractory GERD: what is it? Curr Gastroenterol Rep 2008;10:252-7
   PubMedGoogle Scholar
• Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD)--acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17:537-45
   PubMed Web of Science ®Google Scholar
• Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin Gastroenterol Hepatol 2008;6:393-400
   PubMed Web of Science ®Google Scholar
• Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012;61:1340-54
   PubMed Web of Science ®Google Scholar
• Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006;116:254-60
   PubMed Web of Science ®Google Scholar
• Dent J, Vakil N, Jones R, et al. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut 2010;59:714-21
   PubMed Web of Science ®Google Scholar
• Jones R, Junghard O, Dent J, et al. Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther 2009;30:1030-8
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Jonsson A, Denison H, et al. Concomitant symptoms itemized in the Reflux Disease Questionnaire are associated with attenuated heartburn response to acid suppression. Am J Gastroenterol 2012;107:1354-60
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011;106:1419-25; quiz 1426
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Jonsson A, Denison H, et al. Regurgitation is less responsive to acid suppression than heartburn in patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:612-19
   PubMed Web of Science ®Google Scholar
• Dickman R, Boaz M, Aizic S, et al. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil 2011;17:387-94
   PubMed Web of Science ®Google Scholar
• Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol 2011;9:824-33
   PubMed Web of Science ®Google Scholar
• Wu JC, Lai LH, Chow DK, et al. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil 2011;23:155-60, e31
   PubMed Web of Science ®Google Scholar
• Savarino E, Pohl D, Zentilin P, et al. Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009;58:1185-91
   PubMed Web of Science ®Google Scholar
• Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut 2012;61:501-6
   PubMed Web of Science ®Google Scholar
• Xiao YL, Peng S, Tao J, et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol 2010;105:2626-31
   PubMed Web of Science ®Google Scholar
• Jung HK, Halder S, McNally M, et al. Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. Aliment Pharmacol Ther 2007;26:453-61
   PubMed Web of Science ®Google Scholar
• Becher A, El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011;34:618-27
   PubMed Web of Science ®Google Scholar
• Hungin AP, Hill C, Molloy-Bland M, et al. Systematic review: patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:109-16
   PubMed Web of Science ®Google Scholar
• Hatlebakk JG, Katz PO, Camacho-Lobato L, et al. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther 2000;14:1267-72
   PubMed Web of Science ®Google Scholar
• Gunaratnam NT, Jessup TP, Inadomi J, et al. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006;23:1473-7
   PubMed Web of Science ®Google Scholar
• Barrison AF, Jarboe LA, Weinberg BM, et al. Patterns of proton pump inhibitor use in clinical practice. Am J Med 2001;111:469-73
   PubMed Web of Science ®Google Scholar
• Fass R, Sontag SJ, Traxler B, et al. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006;4:50-6
   PubMed Web of Science ®Google Scholar
• Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000;14:1595-603
   PubMed Web of Science ®Google Scholar
• Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80
   PubMed Web of Science ®Google Scholar
• Stein HJ, Smyrk TC, DeMeester TR, et al. Clinical value of endoscopy and histology in the diagnosis of duodenogastric reflux disease. Surgery 1992;112:796-803; discussion 803-4
   PubMed Web of Science ®Google Scholar
• Miller SM, Goldstein JL, Gerson LB. Cost-effectiveness model of endoscopic biopsy for eosinophilic esophagitis in patients with refractory GERD. Am J Gastroenterol 2011;106:1439-45
   PubMed Web of Science ®Google Scholar
• Garcia-Compean D, Gonzalez Gonzalez JA, Marrufo Garcia CA, et al. Prevalence of eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease symptoms: a prospective study. Dig Liver Dis 2011;43:204-8
   PubMedGoogle Scholar
• Foroutan M, Norouzi A, Molaei M, et al. Eosinophilic esophagitis in patients with refractory gastroesophageal reflux disease. Dig Dis Sci 2010;55:28-31
   PubMed Web of Science ®Google Scholar
• Poh CH, Gasiorowska A, Navarro-Rodriguez T, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc 2010;71:28-34
   PubMed Web of Science ®Google Scholar
• Richter JE. How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol 2007;4:658-64
   PubMedGoogle Scholar
• Francis DO, Rymer JA, Slaughter JC, et al. High economic burden of caring for patients with suspected extraesophageal reflux. Am J Gastroenterol 2013;108:905-11
   PubMed Web of Science ®Google Scholar
• Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001;120:1599-606
   PubMed Web of Science ®Google Scholar
• Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol 2005;100:283-9
   PubMed Web of Science ®Google Scholar
• Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut 2006;55:1398-402
   PubMed Web of Science ®Google Scholar
• Roman S, Bruley des Varannes S, Pouderoux P, et al. Ambulatory 24-h oesophageal impedance-pH recordings: reliability of automatic analysis for gastro-oesophageal reflux assessment. Neurogastroenterol Motil 2006;18:978-86
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Smout A. Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010;32:334-43
   PubMed Web of Science ®Google Scholar
• Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308-28; quiz 329
   PubMed Web of Science ®Google Scholar
• Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: ’on’ or ’off’ proton pump inhibitor? Am J Gastroenterol 2008;103:2446-53
   PubMed Web of Science ®Google Scholar
• Pritchett JM, Aslam M, Slaughter JC, et al. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clin Gastroenterol Hepatol 2009;7:743-8
   PubMed Web of Science ®Google Scholar
• Pandolfino JE, Vela MF. Esophageal-reflux monitoring. Gastrointest Endosc 2009;69:917-30; 930 e1
   PubMed Web of Science ®Google Scholar
• Gawron AJ, Rothe J, Fought AJ, et al. Many patients continue using proton pump inhibitors after negative results from tests for reflux disease. Clin Gastroenterol Hepatol 2012;10:620-5; quiz e57
   PubMed Web of Science ®Google Scholar
• Ponce J, Ortiz V, Maroto N, et al. High prevalence of heartburn and low acid sensitivity in patients with idiopathic achalasia. Dig Dis Sci 2011;56:773-6
   PubMed Web of Science ®Google Scholar
• Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006;166:965-71
   PubMed Web of Science ®Google Scholar
• Pomiecinski F, Yang AC, Navarro-Rodrigues T, et al. Sensitization to foods in gastroesophageal reflux disease and its relation to eosinophils in the esophagus: is it of clinical importance? Ann Allergy Asthma Immunol 2010;105:359-63
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Armstrong D, Hunt RH, et al. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: encomPASS--a cluster-randomized trial. Am J Gastroenterol 2010;105:2341-6
   PubMed Web of Science ®Google Scholar
• Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011;305:1969-77
   PubMed Web of Science ®Google Scholar
• Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-9
   PubMed Web of Science ®Google Scholar
• Ours TM, Fackler WK, Richter JE, et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol 2003;98:545-50
   PubMed Web of Science ®Google Scholar
• Blackshaw LA, Staunton E, Lehmann A, et al. Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol 1999;277:G867-74
   PubMed Web of Science ®Google Scholar
• Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003;52:464-70
   PubMed Web of Science ®Google Scholar
• Wilkerson PM, Stratford J, Jones L, et al. A poor response to proton pump inhibition is not a contraindication for laparoscopic antireflux surgery for gastro esophageal reflux disease. Surg Endosc 2005;19:1272-7
   PubMed Web of Science ®Google Scholar
• Khajanchee YS, Hong D, Hansen PD, et al. Outcomes of antireflux surgery in patients with normal preoperative 24-hour pH test results. Am J Surg 2004;187:599-603
   PubMed Web of Science ®Google Scholar
• Gerson LB, Huff FJ, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2010;105:1266-75
   PubMed Web of Science ®Google Scholar
• Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010;139:409-17
   PubMed Web of Science ®Google Scholar
• Viazis N, Keyoglou A, Kanellopoulos AK, et al. Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012;107:1662-7
   PubMed Web of Science ®Google Scholar
• Krarup AL, Ny L, Astrand M, et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther 2011;33:1113-22
   PubMed Web of Science ®Google Scholar
• Krarup AL, Ny L, Gunnarsson J, et al. Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain. Scand J Gastroenterol 2013;48:274-84
   PubMed Web of Science ®Google Scholar
• Mirbagheri SA, Sadeghi A, Amouie M, et al. Pyloric injection of botulinum toxin for the treatment of refractory GERD accompanied with gastroparesis: a preliminary report. Dig Dis Sci 2008;53:2621-6
   PubMed Web of Science ®Google Scholar
• Bromer MQ, Friedenberg F, Miller LS, et al. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc 2005;61:833-9
   PubMed Web of Science ®Google Scholar
• Corley DA, Katz P, Wo JM, et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003;125:668-76
   PubMed Web of Science ®Google Scholar
• Coron E, Sebille V, Cadiot G, et al. Clinical trial: radiofrequency energy delivery in proton pump inhibitor-dependent gastro-oesophageal reflux disease patients. Aliment Pharmacol Ther 2008;28:1147-58
   PubMed Web of Science ®Google Scholar
• Arts J, Sifrim D, Rutgeerts P, et al. Influence of radiofrequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophagal reflux disease. Dig Dis Sci 2007;52:2170-7
   PubMed Web of Science ®Google Scholar
• Campos GM, Peters JH, DeMeester TR, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg 1999;3:292-300
   PubMed Web of Science ®Google Scholar
• Anvari M, Allen C. Surgical outcome in gastro-esophageal reflux disease patients with inadequate response to proton pump inhibitors. Surg Endosc 2003;17:1029-35
   PubMed Web of Science ®Google Scholar
• Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009;58:295-309
   PubMed Web of Science ®Google Scholar
• Lundell L. Surgical therapy of gastro-oesophageal reflux disease. Best Pract Res Clin Gastroenterol 2010;24:947-59
   PubMed Web of Science ®Google Scholar
• Broeders JA, Draaisma WA, Bredenoord AJ, et al. Impact of symptom-reflux association analysis on long-term outcome after Nissen fundoplication. Br J Surg 2011;98:247-54
   PubMed Web of Science ®Google Scholar
• Bell RC, Hanna P, Brubaker S. Laparoscopic fundoplication for symptomatic but physiologic gastroesophageal reflux. J Gastrointest Surg 2001;5:462-7
   PubMed Web of Science ®Google Scholar
• Broeders JA, Draaisma WA, Bredenoord AJ, et al. Oesophageal acid hypersensitivity is not a contraindication to Nissen fundoplication. Br J Surg 2009;96:1023-30
   PubMed Web of Science ®Google Scholar
• del Genio G, Tolone S, del Genio F, et al. Prospective assessment of patient selection for antireflux surgery by combined multichannel intraluminal impedance pH monitoring. J Gastrointest Surg 2008;12:1491-6
   PubMed Web of Science ®Google Scholar
• Kavitt RT, Higginbotham T, Slaughter JC, et al. Symptom reports are not reliable during ambulatory reflux monitoring. Am J Gastroenterol 2012;107:1826-32
   PubMed Web of Science ®Google Scholar
• Slaughter JC, Goutte M, Rymer JA, et al. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2011;9:868-74
   PubMed Web of Science ®Google Scholar
• Frazzoni M, Conigliaro R, Melotti G. Reflux parameters as modified by laparoscopic fundoplication in 40 patients with heartburn/regurgitation persisting despite PPI therapy: a study using impedance-pH monitoring. Dig Dis Sci 2011;56:1099-106
   PubMed Web of Science ®Google Scholar
• Broeders JA, Roks DJ, Draaisma WA, et al. Predictors of objectively identified recurrent reflux after primary Nissen fundoplication. Br J Surg 2011;98:673-9
   PubMed Web of Science ®Google Scholar
• Hershcovici T, Fass R. Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors. Curr Opin Gastroenterol 2010;26:367-78
   PubMed Web of Science ®Google Scholar
• Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol 2010;24:923-36
   PubMed Web of Science ®Google Scholar
• Richter JE. Duodenogastric Reflux-induced (Alkaline) Esophagitis. Curr Treat Options Gastroenterol 2004;7:53-8
   PubMedGoogle Scholar
• Rubenstein JH, Nojkov B, Korsnes S, et al. Oesophageal hypersensitivity is associated with features of psychiatric disorders and the irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:443-52
   PubMed Web of Science ®Google Scholar
• Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008;27:473-82
   PubMed Web of Science ®Google Scholar